Efficacy and Safety of Telitacicept in IgAN

Exclusion Criteria

• •1. Patients with abnormal laboratory indicators (see study protocol for details).
• •2. Secondary IgA nephropathy such as Henoch-Schonlein purpura, SLE, cirrhosis, etc.
• •3. Use of systemic glucocorticoids/immunosuppressants within 3 months (such as cyclophosphamide, azathioprine, mycophenolate mofetil, leflunomide, tacrolimus, cyclosporine, tripterygium wilfordii, etc.).
• •4. Use of biological agents within 6 months (rituximab, etc.).
• •5. Active infection, such as active tuberculosis, active hepatitis, hepatitis C, herpes zoster, HIV, etc. According to the results of the five hepatitis B test: patients with positive HBsAg should be excluded; patients with negative HBsAg but positive HBcAb, regardless of whether HBsAb is positive or negative, need to test HBV-DNA to determine their situation: if HBV-DNA is positive, the patient needs to be excluded; if HBV-DNA is negative, the patient can participate in the trial.
• •6. COVID-19 infection within 2 weeks before randomization.
• •7. Live vaccine within 4 weeks before randomization.
• •8. History of malignant tumor within five years.
• •9. Uncontrolled hypertension (systolic blood pressure\>140mmHg or diastolic blood pressure\>90mmHg).
• •10. Poorly controlled diabetes (glycosylated hemoglobin\>8%).
• •11. Pregnant women and breastfeeding women.
• •12. Participating in other clinical trials at the same time.
• •13. Surgery, chemotherapy, radiotherapy and other treatments are planned during the study.
• •14. Other reasons judged by researchers as unsuitable for inclusion in the study.